The duty to warn in pharmaceutical law runs primarily from the manufacturer to the prescribing physician, a doctrine called the "learned intermediary rule." However, when manufacturers allegedly fail to provide adequate safety information to physicians, that failure can be the foundation of a claim, even if the prescription itself was legitimate
Additional potential effects include[6]: Loss of bone density Loss of strength Fatigue Hair loss Weakened immune function Nutrient deficiencies Who Is Semaglutide Recommended For
This is due to many different factors, examples being - genetic predisposition, hormonal imbalances, metabolic syndromes, autoimmune conditions, and many different other factors
Adjustment to the Amount in Controversy Threshold Amounts for Calendar Year 2026." Federal Register, December 4, 2025